sur Mainz BioMed N.V.
DoctorBox Integrates ColoAlert® for Enhanced Home Cancer Screening
Mainz Biomed N.V., a leader in genetic diagnostics, has announced the addition of its ColoAlert® to DoctorBox's healthcare offerings. This move highlights a pivotal expansion in Mainz Biomed's European strategy, emphasizing home-based colorectal cancer screening. Lab analyses will be conducted by the European Oncology Lab, underscoring a focus on personalized preventive care.
Colorectal cancer remains prevalent but preventable, with 60,000 cases in Germany annually. The partnership between Mainz Biomed and DoctorBox aims to provide easy access to early detection, lowering barriers to preventive screening. DoctorBox, a major app in preventive healthcare, serves over a million users, offering comprehensive health solutions including DNA-based tests.
Mainz Biomed, currently seeking FDA approval in the US, continues to expand its diagnostic solutions, further advancing early cancer detection technologies.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.